Daily Newsletter

21 September 2023

Daily Newsletter

21 September 2023

Regulus reports positive Phase Ib data for kidney disease treatment

RGLS8429 was demonstrated to be well tolerated in trial participants without any safety findings reported.

Vishnu Priyan September 21 2023

Regulus Therapeutics has reported positive topline data from the first cohort of its Phase Ib multiple-ascending dose (MAD) clinical trial of RGLS8429 to treat autosomal-dominant polycystic kidney disease (ADPKD).

The double-blind, placebo-controlled trial is analysing the tolerability, safety, pharmacokinetics and pharmacodynamics of RGLS8429 in adult ADPKD patients.

The first cohort enrolled 12 participants, who were randomised into a 3:1 ratio to receive RGLS8429 1mg/kg or placebo on alternate weeks for a total of three months.

According to the trial data, RGLS8429 was demonstrated to be well tolerated in participants who received the active drug without any safety findings.

In RGLS8429 arms, improvement in urinary polycystin 1 and 2 (PC1 and PC2) was reported. 

The protein products of PKD1 and PKD2 genes, PC1 and PC2 levels are inversely linked to the severity of the disease.

The company is currently dosing subjects in the second cohort with 2mg/kg of RGLS8429 or placebo with the same dosing regimen as the first cohort.

RGLS8429 is an oligonucleotide that can hinder miR-17.

Regulus Therapeutics CEO Jay Hagan said: “These data strengthen our conviction in the potential of our lead compound, RGLS8429, to address the underlying genetic drivers of ADPKD.

“We look forward to providing additional updates as we continue to make progress with the second cohort of this Phase Ib study and initiate recruitment for the third cohort next month.”

The company also concluded a 27-week toxicity study of RGLS8429 in mice with data showing no drug-associated toxicity at any dose levels up to 300mg/kg given on alternate weeks.

Multiple Myeloma (MM) pipeline dominated by CAR-T cells

The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close